The news is directly related to Madrigal Pharmaceuticals. While the 'Outperform' rating is maintained, the lowering of the price target might indicate a potential slowdown in the company's growth or a reassessment of its valuation. This could have a neutral impact on the stock price in the short term as the positive 'Outperform' rating is balanced by the lower price target.